Gene Expression Algorithm for Prostate Cancer Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prognostic tools for prostate cancer lack accuracy in distinguishing between men who require immediate definitive therapy and those who can defer treatment, leading to over-treatment and potential missed opportunities for curative therapy due to inadequate risk estimation based on PSA levels and clinical tumor stage.
Innovation Solution
A molecular diagnostic assay measuring the expression levels of specific genes or gene subsets from prostate cancer patients to predict clinical outcomes, using an algorithm that assigns RNA transcripts to gene groups and calculates a quantitative score for predicting the likelihood of clinical outcomes such as recurrence or upgrading/upstaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PSA levels and clinical tumor stage are used for prognosis, then the diagnostic process is simple and widely available, but the prediction accuracy of clinical outcomes is insufficient
Solution Approach 1:
The gene expression profile is divided into multiple gene groups (Group 1-6) with specific genes assigned to each group. The assay measures expression levels of individual genes or subsets of genes within these groups, allowing the complex diagnostic problem to be segmented into manageable components that can be measured and evaluated systematically
Solution Approach 2:
Gene expression levels serve as intermediary biomarkers that bridge the gap between simple clinical parameters (PSA, tumor stage) and actual clinical outcomes. These molecular intermediaries provide more direct information about tumor biology and aggressiveness, improving prediction accuracy without requiring direct observation of complex clinical outcomes
2Reliability
If immediate definitive therapy is provided to all diagnosed patients, then the risk of recurrence and death is reduced, but unnecessary treatment and toxicity increase
Solution Approach 1:
The assay enables local quality differentiation in treatment approach by identifying specific patient subgroups with different risk profiles. High-risk patients receive aggressive definitive therapy while low-risk patients receive surveillance, matching treatment intensity to individual patient needs and minimizing unnecessary toxicity in low-risk populations
Solution Approach 2:
The invention changes the risk stratification parameter from simple clinical variables (PSA, stage) to molecular parameters (gene expression profiles). This parameter change allows for more precise identification of patients who truly need aggressive therapy versus those who can be safely managed with surveillance, reducing overtreatment-related harm
3Object-generated harmful factors
If active surveillance is used for low-risk patients, then treatment toxicity is reduced, but the opportunity for curative therapy may be missed
Solution Approach 1:
The gene expression assay provides feedback on tumor biology and aggressiveness, enabling dynamic decision-making. Patients initially placed on surveillance can be re-evaluated using the molecular profile to determine if they should transition to definitive therapy, ensuring that curative opportunities are not missed while maintaining a less toxic initial approach for truly low-risk patients
Data Source
AI summary
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.